WO2003030870A1 - Microspheres biodegradables a liberation prolongee et leur procede de preparation - Google Patents
Microspheres biodegradables a liberation prolongee et leur procede de preparation Download PDFInfo
- Publication number
- WO2003030870A1 WO2003030870A1 PCT/FR2002/003447 FR0203447W WO03030870A1 WO 2003030870 A1 WO2003030870 A1 WO 2003030870A1 FR 0203447 W FR0203447 W FR 0203447W WO 03030870 A1 WO03030870 A1 WO 03030870A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- microspheres
- active principle
- weight
- present
- release
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
Definitions
- the present invention relates to a process for preparing a pharmaceutical composition in the form of microspheres with sustained release of a water-soluble active principle.
- the subject of the invention is also microspheres capable of being obtained by the implementation of this method, having a continuous release of active principle over a period of more than two months, advantageously at least three months.
- compositions in the form of microspheres based on biodegradable polymers and copolymers, containing pharmacologically active compounds, and designed for a controlled and prolonged release of said compounds, have been described in various documents of the state of the prior art.
- Such pharmaceutical compositions are of great interest for the treatment of various diseases requiring a continuous and prolonged release of active ingredient.
- the formulations developed so far for the development of this type of composition have various drawbacks and few of them reach the stage of clinical trials.
- This release generally leads to a sudden increase in plasma concentrations of the drug, which in many cases leads to toxicological problems unacceptable to humans.
- This “burst” release also leads to a reduction in the duration of activity of the pharmaceutical composition, due to the sudden and rapid release of a large amount of said active ingredient following administration of the composition.
- a second problem resides in the fact that ineffective encapsulation rates are generally obtained by using the usual microencapsulation methods, in particular when the active principle is a water-soluble drug.
- a third problem which it is necessary to solve during the development of these formulations is the instability of the active principles in the face of the rigorous conditions employed during the manufacture of the microspheres, such as high temperatures or prolonged contacting of the active ingredient with organic solvents during the solvent evaporation step.
- additives such as sugars, oils, wax, proteins, polymers, salts, or acids, have been used in the preparation of pharmaceutical compositions in the form of microspheres.
- These additives which act as substances retaining the drug in the microsphere, make it possible to increase the efficiency of the microencapsulation process and even possibly to protect the active principle during the process, by playing the role of stabilizing agents.
- microspheres can lead to problems of interaction between the additives and the active principle or the polymer-based matrix, thereby inducing problems with regard to toxicology and pharmacological activity of the drug.
- the additives which retain the active ingredient inside the microspheres during the manufacturing process, influence the release profile of the active ingredient contained in the microspheres, which can prevent a continuous release of said active ingredient following administration.
- microspheres Other microencapsulation methods have also been developed in an attempt to increase the efficiency of the microencapsulation of the active principle within the microspheres, based on the use of mixtures of organic solvents, but such methods lead stability problems of the active ingredient during the microsphere manufacturing process.
- microspheres based on active principle and biodegradable matrix copolymer of the d, l-lactide-co-glycolide type having a specific molecular weight and a specific lactic acid / glycolic acid ratio , by a rapid process of the multiple emulsion-solvent evaporation type, without using any additive or modulating agent as is the case in patent FR 2 718 642, made it possible to obtain microspheres having a continuous and sustained release of active ingredient over a period of more than two months, while presenting a restricted "burst" effect.
- Such an encapsulation process which employs mild conditions which are not very aggressive for the medicament, also makes it possible to preserve the stability of said medicament and to obtain a homogeneous distribution of the medicament within the microsphere obtained.
- the Applicant has surprisingly discovered that the use of an osmotic agent during the step of emulsifying the first emulsion in the external aqueous phase made it possible to obtain a particularly high encapsulation efficiency by increasing the content of active ingredient encapsulated within the polymer matrix, and influence the size of the microspheres.
- the object of the present invention relating to a rapid encapsulation process, very effective and not very aggressive for the active principle, thus makes it possible to obtain microspheres, based on water-soluble active principle and of matrix copolymer of type d, l -lactide-co-glycolide, having a continuous and sustained release of active ingredient over a period of more than two months, preferably at least three months, while having a weak "burst" effect in the hours following administration of composition.
- the present invention thus relates to a process for the preparation of a pharmaceutical composition in the form of microspheres with prolonged release of a water-soluble active principle, characterized in that it comprises the following sequence of steps: - dissolution of the active principle in an appropriate amount of water, emulsification of the aqueous solution of active principle thus obtained with a solution of a matrix copolymer d, l-lactide-co-glycolide, of average molecular weight between 40,000 and 80,000 and having a proportion lactic acid / glycolic acid between 50/50 and 80/20, dissolved in a chlorinated hydrocarbon, leading to a first microfine and homogeneous emulsion, the size of said emulsion being advantageously less than 1 ⁇ m, emulsification of said first emulsion thus obtained in an external aqueous phase, containing a surfactant, an agent increasing the viscosity and an osmotic agent, - extraction-evaporation of the solva nt to obtain
- the water-soluble active principle usable in the context of the process according to the present invention is advantageously chosen from the group consisting of peptides, proteins, vaccines, antibiotics, antidepressants, analgesics, anti-inflammatories and cytostatics. Even more advantageously according to the present invention, the active principle is 5-OxoPro-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-ProNHEt or one of its salts. This active ingredient is an analogue of the hormone GnRH with agonist activity.
- the first step of dissolving the active principle in water to form an internal aqueous phase is carried out without the addition of any substance which retains the active principle, nor of stabilizing agent of the emulsion and without any operation intended to increase the viscosity.
- the active principle is dissolved in the internal aqueous phase without any additive or adjuvant whatsoever.
- concentrations used in the internal aqueous phase in the context of the present invention are a function of the solubility of the active principle in water, of the characteristics of said active principle and of the duration of release which it is desired to obtain.
- the active principle is present at a concentration of between 0.01 and 95% by weight, advantageously between 0.5 and 40% by weight, relative to the total weight of the internal aqueous phase.
- the formation of the first emulsion can in particular be carried out using an ultrasonic device or a homogenizer.
- the matrix copolymer which can be used according to the present invention for preparing microspheres by W / O / W must be able to be dissolved in an appropriate volatile solvent, such as halogenated alkanes.
- the solvent is a chlorinated hydrocarbon such as methylene chloride, chloroform, chloroethane, dichloroethane, or trichloroethane.
- the chlorinated hydrocarbon is methylene chloride.
- the matrix copolymer d, l-lactide-co-glycolide which can be used in the process according to the present invention has the cumulative advantages of being insoluble in water, of being biodegradable (such a copolymer is absorbed without accumulating in the organs vital and is ultimately completely eliminated), to be biocompatible with the organism and to be perfectly tolerated by it, and ultimately to have a minimal inflammatory response.
- the solution of the matrix copolymer d, l-lactide-co-glycolide is obtained by dissolving the copolymer in a chlorinated hydrocarbon such as methylene chloride, without the addition of a release modulating agent.
- a release modulating agent is not suitable for the manufacture of microspheres designed for release over a period of more than two months.
- the selection carried out on the copolymer, with a specific molecular weight and a specific lactic acid / glycolic acid ratio, combined with the fact of not using a release modulating agent in the process which is the subject of the present invention thus has the advantage of '' obtain microspheres with a continuous and sustained release of active ingredient over a period of more than two months, preferably at least at least three months, while exhibiting a restricted burst effect in the hours following the administration of the composition.
- concentrations of the polymer dissolved in the organic solution of methylene chloride depend on the active ingredient and the desired rate of release.
- the matrix copolymer is present at a concentration of between 5 and 50% by weight, relative to the total weight of the solution consisting of the copolymer dissolved in the chlorinated hydrocarbon.
- the external aqueous phase contains a surfactant such as polysorbate 80, an agent increasing the viscosity such as polyvinylpyrrolidone and an osmotic agent such as mannitol or sodium chloride.
- a surfactant such as polysorbate 80
- an agent increasing the viscosity such as polyvinylpyrrolidone
- an osmotic agent such as mannitol or sodium chloride.
- the external aqueous phase contains a solution of polysorbate 80, polyvinylpyrrolidone and mannitol or sodium chloride.
- the external aqueous phase contains a solution of polysorbate 80, polyvinylpyrrolidone and sodium chloride.
- the surfactant is present at a concentration of between 0.1 and 0.5% by weight
- the agent increasing the viscosity is present at a concentration of between 1 and 25% by weight
- the osmotic agent is present at a concentration of between 0.1 and 10% by weight, relative to the total weight of the external aqueous phase.
- the composition of the external aqueous phase is decisive for the formation of the second emulsion (emulsification of the first emulsion), and it is therefore decisive for the manufacture of the microspheres. It thus contributes to the rapid stabilization of the microspheres, it influences the encapsulation efficiency of the active ingredients and constitutes an essential factor for controlling the size of the final microspheres and their morphology.
- the solvent is rapidly removed at room temperature and under atmospheric pressure, according to a continuous evaporator system consisting of a slope of adequate length over which the suspension of microspheres flows in a thin layer.
- a continuous evaporator system consisting of a slope of adequate length over which the suspension of microspheres flows in a thin layer.
- the rapid stabilization of the polymer matrix obtained during this extraction-evaporation step of the organic solvent also makes it possible to obtain a homogeneous distribution of the active substance throughout the microsphere (thus making it possible to obtain a low concentration of active ingredient encapsulated by of the surface of the microsphere), thus helping to reduce the phenomenon of "burst" release, following the administration of the microspheres.
- the fact of implementing the process at ambient temperature and under atmospheric pressure makes it possible to avoid problems such as the alteration of the thermolabile products or the breaking of the microspheres when the vacuum is used during the extraction step. -evaporation.
- the process for manufacturing the microspheres according to the present invention comprises the following steps:
- a certain amount of active ingredient is dissolved in a volume of water.
- This solution emulsifies, using an ultrasound device for example, in a volume of methylene chloride containing a polylactide-co-glycolide copolymer, of average molecular weight between 40,000 and 80,000 daltons and having a proportion of lactic acid to glycolic acid between 50/50 and 80/20.
- the first emulsion which results therefrom must be micro-fine and homogeneous, thus making it possible to spread the active principle over the entire polymer matrix, ensuring the reproducibility of the different batches, without the need to use surfactants or other adjuvants.
- the first emulsion is in turn emulsified in an external phase, consisting of an aqueous solution of polysorbate 80 as a surfactant, of polyvinylpyrrolidone as a viscosity-increasing agent and of mannitol or NaCl in as an osmotic agent, with stirring for a short time.
- an external phase consisting of an aqueous solution of polysorbate 80 as a surfactant, of polyvinylpyrrolidone as a viscosity-increasing agent and of mannitol or NaCl in as an osmotic agent, with stirring for a short time.
- the double emulsion is diluted with water, then the suspension is passed under atmospheric conditions over a continuous evaporator system consisting of a slope of adequate length over which flows in a layer thin the suspension of microspheres.
- This system makes it possible to promote contact between the emulsion and the atmosphere, which reduces the duration of evaporation of the organic solvent, and to increase the stabilization of the active principle.
- the microspheres obtained in this way are then recovered by filtration, washed with water and dried by lyophilization.
- microspheres obtained according to the process which is the subject of the present invention are microspheres with a high content of active principle, allowing continuous release in vivo of the drug over a period of more than two months, preferably at least 3 months, with a weak burst effect after parenteral administration of the microspheres.
- the present invention also relates to the microspheres capable of being obtained by implementing the method according to the present invention, having a continuous release of active principle over a period of more than two months, advantageously over a period of at least three months.
- the active principle is present at a concentration of between 0.5 and 20% by weight, advantageously between 5 and 15% by weight, relative to the total weight of the microspheres.
- the size of the microspheres is less than 250 ⁇ m, even more advantageously less than 90 ⁇ m. This size is adequate for administration of the microspheres.
- microspheres according to the present invention are advantageously administered parenterally, even more advantageously in the form of intramuscular, subcutaneous, intra-arterial injections or in the place where a tumor is found.
- the microspheres are preferably dispersed in a standard aqueous medium with dispersing agents and isotonizing agents.
- Example 1 (comparative):
- Arg-ProNHEt acetate are prepared according to the manufacturing process described in the publication Advanced Drug Delivery Reviews, 28 (1997), 43-70, which differs from the process which is the subject of the present invention.
- the microspheres are produced by dissolving an appropriate quantity of active principle in water, then by emulsifying the aqueous solution of active principle thus obtained with a solution of a polylactide (100% lactide) , with an average molecular weight of 15,000, in methylene chloride.
- the emulsification is carried out with an agitator, with vigorous stirring.
- the first Ei / H emulsion has been formed, it is in turn emulsified, in order to obtain an E emulsion !
- Example 1 The main differences between the microspheres obtained according to the method described in the document of the prior art cited above and those obtained according to the method object of the present invention lie in: the choice of the polymer.
- the polymer used is a polylactide (100% lactide), with an average molecular weight of 15,000. It is a standard polymer, according to this document, for a sustained release of 5-OxoPro-His-Trp-Ser-T r-D-Leu-Leu-Arg-ProNHEt acetate over a period of three months.
- the composition of the aqueous external phase which consists of a polyvinyl alcohol (0.25%) in Example 1. the evaporation system of the organic solvent. In Example 1, the double emulsion is stirred for several hours.
- the 5-OxoPro-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-ProNHEt acetate is dissolved in water, then the aqueous solution of active principle is emulsified, using an ultrasound device, in a methylene chloride solution containing 15% of a copolymer d, l-lactide-co-glycolide, this copolymer having a weight average molecular weight of 63,000 daltons (inherent viscosity of about 0.6 dl / g) and a proportion of lactic acid to glycolic acid of 75/25.
- the first emulsion is in turn emulsified with an aqueous solution consisting of 0.25% polysorbate 80, 7% polyvinylpyrrolidone and 5% mannitol, with stirring, using a propeller stirrer with blades.
- the double emulsion is passed, under atmospheric conditions, over a continuous evaporator system consisting of a slope of adequate length over which the suspension of microspheres flows in a thin layer.
- a continuous evaporator system consisting of a slope of adequate length over which the suspension of microspheres flows in a thin layer.
- the organic solvent is quickly evaporated, leading to rapid stabilization of the polymer matrix.
- the microspheres are finally recovered by filtration, washed with water and then dried under lyophilization.
- the final charge of the microspheres in drug is from 9 to 11% by weight.
- Microspheres are produced by following the process described in Example 2, using 5% sodium chloride in the external aqueous phase as an osmotic agent, instead of 5% mannitol.
- compositions prepared according to the process of the prior art of Example 1 agree with the results obtained in vitro (Example 3) and demonstrate that the formulations prepared in accordance with the process of the present invention exhibit a much less burst release than the burst release. "compositions prepared according to the process of the prior art of Example 1.
- Example 5 In order to supplement the previous results (Examples 3 and 4), an in-depth study of the in vivo release of active ingredient during the first 24 hours following the administration of the microspheres was carried out.
- the microspheres of Example 1 After 2, 3, 4, 8 and 24 hours, the microspheres of Example 1 have respectively serum concentrations of 103.7; 50.1; 30.3; 9.5 and 3.8 ⁇ g / 1, while the microspheres of Example 2 have values of 28.0 respectively; 5.5; 4.5; 9.3 and 1.0 ⁇ g / 1 respectively.
- the complete release profile of 5-OxoPro-His-T ⁇ -Ser-Tyr-D-Leu-Leu-Arg-ProNHEt acetate from the microspheres prepared according to Example 2 is studied in rats.
- the object of the study is to demonstrate that, following the phenomenon of release "burst" (which takes place systematically, but which is relatively weak compared to microspheres described in the prior art), the microspheres obtained according to the method of the present invention release the peptide continuously over a period of several months.
- Example 4 the microspheres are suspended in a standard aqueous vehicle for their subcutaneous administration in a dorsal area previously shaved in rats.
- the dose administered to each animal is 3.6 mg of 5-OxoPro-His-T ⁇ -Ser-Tyr-D-Leu-Leu-Arg-ProNHEt encapsulated acetate.
- Example 7 Study of the in vivo biological activity of 5-OxoPro-His-T ⁇ -Ser-Tyr-D-Leu-
- 5-OxoPro-His-T ⁇ -Ser-Tyr-D-Leu-Leu-Arg-ProNHEt acetate is a potent agonist analogue of the hormone LH-RH, which stimulates the secretion of gonadotropins by the pituitary gland and steroidogenesis in the genitals in acute doses.
- LH-RH lactidomasine
- Examples 8 to 10 is to show the various advantages of the microspheres prepared according to the process which is the subject of the present invention compared to the microspheres prepared according to the process described in patent FR 2 718 642.
- the main differences between the present invention and the invention described in patent FR 2 718 642 are the following: • No release modulating agent used in the process of the present invention.
- Microspheres are prepared following the manufacturing process described in Example 2, using as organic phase a solution of methylene chloride containing 30% of a copolymer d, l-lactide-co-glycolide, having a weight average molecular weight of 34,000 daltons (inherent viscosity of about 0.4 dl / g) and a proportion of lactic acid to glycolic acid of 50/50 as well as different amounts (examples 8.1, 8.2 and 8.3) of a pory (d-lactide having an average molecular weight of 2,000 daltons (PLA 2,000).
- Example 8.1 0% of PLA 2,000.
- Example 8.2 2.5% of PLA 2,000.
- Example 8.3 5% of PLA 2,000.
- the external aqueous phase is an aqueous solution composed of 0.25% of polysorbate 80, 4% of polyvinylpyrrolidone and 5% of mannitol.
- the initial in vitro release of 5-OxoPro-His-T ⁇ -Ser-Tyr-D-Leu-Leu-Arg-ProNHEt acetate from the microspheres prepared according to Examples 8.1, 8.2 and 8.3 is carried out in a phosphate buffer.
- EXAMPLE 9 Effect of the Modulating Release Agent on the Pharmacodynaic Profile and Selection of the Polymer for a Prolonged Release Over Three Months
- the effect of the polymer composition of the microspheres on the release of the active ingredient is studied in a pharmacodynamic study carried out in rats.
- the microspheres are prepared by following the manufacturing process described in Example 2, using different types of polymer:
- Example 9.1 97.5% mixture of a d, l-lactide-co-glycolide copolymer, having an average molecular weight of 34,000 daltons and a proportion of lactic acid to glycolic acid of 50/50, and 2.5% of a poly (d, l-lactide) having an average molecular weight of 2,000 daltons (release modulating agent).
- Example 9.2 Copolymer d, l-lactide-co-glycolide, having an average molecular weight of 34,000 daltons and a proportion of lactic acid to glycolic acid of 50/50.
- Example 9.3 Copolymer d, l-lactide-co-glycolide, having an average molecular weight of 63,000 daltons and a proportion of lactic acid to glycolic acid of 75/25.
- Microspheres are prepared by following the manufacturing process described in Example 2, using as external aqueous phase a solution composed of 0.25% of Polysorbate 80 and 4% of polyvinylpyrrolidone.
- Microspheres are prepared following the manufacturing process described in Example 10.1, adding between 2.5% and 5% of mannitol in the external aqueous phase as an osmotic agent.
- Microspheres are prepared following the manufacturing process described in Example 10.1, adding between 2.5% and 5% of sodium chloride in the external aqueous phase as an osmotic agent.
- the size and peptide content of the microspheres depend on the presence of the osmotic agent in the external aqueous phase.
- the addition of mannitol or NaCl as osmotic agent increases the encapsulation efficiency, ie the percentage of microencapsulated active ingredient (content).
- the type and amount of the osmotic agent added may also allow particle size control.
- NaCl is advantageously used as an osmotic agent, since it has been demonstrated that under identical conditions of agitation and viscosity, sodium chloride allows a greater reduction in the particle size as mannitol, without producing a decrease in the encapsulation efficiency.
- Example 11 Effect of the concentration of the viscosity-increasing agent ( “ viscosifying agent " ) present in the external aqueous phase on the particle size Formulation 11.1:
- Microspheres are prepared by following the manufacturing process described in example 2, but without active principle, using as external aqueous phase a solution composed of 0.25% of Polysorbate 80, 5% of mannitol and 6.8 % of polyvinylpyrrolidone.
- Microspheres are prepared by following the manufacturing process described in example 2, but without active principle, using as external aqueous phase a solution composed of 0.25% of Polysorbate 80, 5% of mannitol and 8.0 % of polyvinylpyrrolidone.
- Example 10.2 developed with an external aqueous phase composed of 0.25% of Polysorbate 80, 5% of mannitol and 4% of polyvinylpyrrolidone, made it possible to obtain a particle size of 43.8 ⁇ m. By increasing the concentration of viscosifier, it can be seen that a notable reduction in the size of the particles is obtained as shown in Table 5 above. Thus, the size of the microspheres depends on the presence of the viscosifying agent in the external aqueous phase, and on its concentration.
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003533903A JP2005509611A (ja) | 2001-10-10 | 2002-10-10 | 徐放型生物分解性微小球およびその製造方法 |
BRPI0213226A BRPI0213226B1 (pt) | 2001-10-10 | 2002-10-10 | processo de preparação de uma composição farmacêutica sob forma de microesferas com liberação prolongada de um princípio ativo hidrossolúvel, e, microesferas |
CA2463358A CA2463358C (fr) | 2001-10-10 | 2002-10-10 | Microspheres biodegradables a liberation prolongee et leur procede de preparation |
ES02793162.5T ES2541908T3 (es) | 2001-10-10 | 2002-10-10 | Microesferas biodegradables de liberación prolongada y su procedimiento de preparación |
AU2002358831A AU2002358831B2 (en) | 2001-10-10 | 2002-10-10 | Prolonged release biodegradable microspheres and method for preparing same |
MXPA04003433A MXPA04003433A (es) | 2001-10-10 | 2002-10-10 | Microesferas biodegradables de liberacion prolongada y metodo para preparar las mismas. |
EP02793162.5A EP1450766B1 (fr) | 2001-10-10 | 2002-10-10 | Microspheres biodegradables a liberation prolongee et leur procede de preparation |
US10/492,417 US7691412B2 (en) | 2001-10-10 | 2002-10-10 | Prolonged release biodegradable microspheres and method for preparing same |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200102261A ES2194590B2 (es) | 2001-10-10 | 2001-10-10 | Microesferas biodegradables con liberacion prolongada y su procedimiento de preparacion. |
ES0102261 | 2001-10-10 | ||
FR01/13031 | 2001-10-10 | ||
FR0113031A FR2830448B1 (fr) | 2001-10-10 | 2001-10-10 | Microspheres biodegradables a liberation prolongee et leur procede de preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003030870A1 true WO2003030870A1 (fr) | 2003-04-17 |
Family
ID=26156245
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2002/003447 WO2003030870A1 (fr) | 2001-10-10 | 2002-10-10 | Microspheres biodegradables a liberation prolongee et leur procede de preparation |
Country Status (10)
Country | Link |
---|---|
US (1) | US7691412B2 (fr) |
EP (1) | EP1450766B1 (fr) |
JP (2) | JP2005509611A (fr) |
CN (1) | CN100518828C (fr) |
AU (1) | AU2002358831B2 (fr) |
BR (1) | BRPI0213226B1 (fr) |
CA (1) | CA2463358C (fr) |
ES (1) | ES2541908T3 (fr) |
MX (1) | MXPA04003433A (fr) |
WO (1) | WO2003030870A1 (fr) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003252751A (ja) * | 2001-12-26 | 2003-09-10 | Takeda Chem Ind Ltd | 新規マイクロスフェアおよびその製造法 |
US9492400B2 (en) | 2004-11-04 | 2016-11-15 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
WO2007070682A2 (fr) | 2005-12-15 | 2007-06-21 | Massachusetts Institute Of Technology | Systeme de criblage de particules |
CA2648099C (fr) | 2006-03-31 | 2012-05-29 | The Brigham And Women's Hospital, Inc | Systeme pour l'administration ciblee d'agents therapeutiques |
WO2007150030A2 (fr) * | 2006-06-23 | 2007-12-27 | Massachusetts Institute Of Technology | Synthèse microfluidique de nanoparticules organiques |
US20100144845A1 (en) * | 2006-08-04 | 2010-06-10 | Massachusetts Institute Of Technology | Oligonucleotide systems for targeted intracellular delivery |
CN101541316A (zh) * | 2006-10-05 | 2009-09-23 | 万能药生物有限公司 | 可注射的储库组合物及其制备方法 |
KR100816065B1 (ko) * | 2006-11-27 | 2008-03-24 | 동국제약 주식회사 | 초기 방출억제 특성이 우수한 서방출성 마이크로캡슐의제조방법 및 이에 의해 제조되는 마이크로캡슐 |
WO2008098165A2 (fr) | 2007-02-09 | 2008-08-14 | Massachusetts Institute Of Technology | Bioréacteur oscillant pour la culture de cellules |
WO2008124632A1 (fr) * | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Nanoparticules assistées par des composés amphiphiles pour délivrance ciblée |
UA99830C2 (uk) * | 2007-06-06 | 2012-10-10 | Дебио Ресшерчи Фармасютикю С.А. | Фармацевтична композиція з пролонгованим вивільненням, виготовлена з мікрочастинок |
SI2644594T1 (sl) * | 2007-09-28 | 2017-10-30 | Pfizer Inc. | Ciljanje rakavih celic z uporabo nanodelcev |
EP3424525A1 (fr) | 2007-10-12 | 2019-01-09 | Massachusetts Institute Of Technology | Nanotechnologie de vaccin |
CA2728176C (fr) | 2008-06-16 | 2017-07-04 | Bind Biosciences, Inc. | Nanoparticules polymeres pharmacologiquement chargees et leurs methodes de fabrication et d'utilisation |
ES2721850T3 (es) * | 2008-06-16 | 2019-08-05 | Pfizer | Nanopartículas poliméricas terapéuticas que comprenden alcaloides vinca y procedimientos de fabricación y uso de las mismas |
US8613951B2 (en) * | 2008-06-16 | 2013-12-24 | Bind Therapeutics, Inc. | Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same |
EP2334288B1 (fr) * | 2008-09-18 | 2021-05-19 | Evonik Corporation | Procédé de micro-encapsulation avec un solvant et un sel |
US8591905B2 (en) | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
US8563041B2 (en) * | 2008-12-12 | 2013-10-22 | Bind Therapeutics, Inc. | Therapeutic particles suitable for parenteral administration and methods of making and using same |
JP2012512175A (ja) * | 2008-12-15 | 2012-05-31 | バインド バイオサイエンシズ インコーポレイテッド | 治療薬を徐放するための長時間循環性ナノ粒子 |
TR201906255T4 (tr) | 2009-12-11 | 2019-05-21 | Pfizer | Terapötik partiküllerin liyofilize edilmesine yönelik stabil formülasyonlar. |
EP2515942B1 (fr) | 2009-12-15 | 2020-02-12 | Pfizer Inc. | Compositions de nanoparticules polymères à visée thérapeutique à base de copolymères à température de transition vitreuse élevée ou poids moléculaires élevés |
EA032943B1 (ru) | 2012-09-17 | 2019-08-30 | Пфайзер Инк. | Способ получения терапевтических наночастиц (варианты) и терапевтическая наночастица (варианты) |
TWI636798B (zh) | 2014-03-14 | 2018-10-01 | 輝瑞大藥廠 | 包含治療劑之治療性奈米顆粒及其製造及使用方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0469520A2 (fr) * | 1990-08-01 | 1992-02-05 | Sandoz Ag | Préparation de polyactides et purification de ceux-ci |
EP0582459A2 (fr) * | 1992-08-07 | 1994-02-09 | Takeda Chemical Industries, Ltd. | Production de microcapsules de médicaments solubles dans l'eau |
WO1995028149A1 (fr) * | 1994-04-15 | 1995-10-26 | Pierre Fabre Medicament | Microspheres biodegradables a liberation controlee et leur procede de preparation |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE634668A (fr) | 1962-07-11 | |||
JP3372558B2 (ja) * | 1990-09-14 | 2003-02-04 | 中外製薬株式会社 | マイクロカプセル型徐放性製剤及びその製造法 |
JPH07196479A (ja) | 1994-01-04 | 1995-08-01 | Unitika Ltd | マイクロカプセルの製造法 |
ES2078182B1 (es) * | 1994-04-15 | 1996-07-01 | Pierre Fabre Iberica S A | Procedimiento para la preparacion de microesferas biodegradables con liberacion controlada y microesferas correspondientes. |
JPH08259460A (ja) * | 1995-01-23 | 1996-10-08 | Takeda Chem Ind Ltd | 徐放性製剤の製造法 |
AU4611496A (en) * | 1995-02-28 | 1996-09-18 | Innapharma, Inc. | Elcatonin controlled release microsphere formulation for treatment of osteoporosis |
JP2001522812A (ja) * | 1997-11-07 | 2001-11-20 | カイロン コーポレイション | Igf−1持続放出性処方物の作製方法 |
US6740634B1 (en) | 1998-01-16 | 2004-05-25 | Takeda Chemical Industries, Ltd. | Sustained release compositions, process for producing the same and utilization thereof |
JP4536837B2 (ja) * | 1998-01-21 | 2010-09-01 | 武田薬品工業株式会社 | 徐放性製剤の製造法 |
EP1044683A1 (fr) * | 1999-04-15 | 2000-10-18 | Debio Recherche Pharmaceutique S.A. | Procédé de dispersion à une étape pour la microencapsulation de substances solubles dans l'eau |
-
2002
- 2002-10-10 MX MXPA04003433A patent/MXPA04003433A/es active IP Right Grant
- 2002-10-10 ES ES02793162.5T patent/ES2541908T3/es not_active Expired - Lifetime
- 2002-10-10 US US10/492,417 patent/US7691412B2/en not_active Expired - Fee Related
- 2002-10-10 JP JP2003533903A patent/JP2005509611A/ja active Pending
- 2002-10-10 EP EP02793162.5A patent/EP1450766B1/fr not_active Expired - Lifetime
- 2002-10-10 BR BRPI0213226A patent/BRPI0213226B1/pt not_active IP Right Cessation
- 2002-10-10 AU AU2002358831A patent/AU2002358831B2/en not_active Ceased
- 2002-10-10 CA CA2463358A patent/CA2463358C/fr not_active Expired - Lifetime
- 2002-10-10 WO PCT/FR2002/003447 patent/WO2003030870A1/fr active Application Filing
- 2002-10-10 CN CNB02824575XA patent/CN100518828C/zh not_active Expired - Fee Related
-
2010
- 2010-03-03 JP JP2010046540A patent/JP2010174021A/ja not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0469520A2 (fr) * | 1990-08-01 | 1992-02-05 | Sandoz Ag | Préparation de polyactides et purification de ceux-ci |
EP0582459A2 (fr) * | 1992-08-07 | 1994-02-09 | Takeda Chemical Industries, Ltd. | Production de microcapsules de médicaments solubles dans l'eau |
WO1995028149A1 (fr) * | 1994-04-15 | 1995-10-26 | Pierre Fabre Medicament | Microspheres biodegradables a liberation controlee et leur procede de preparation |
Non-Patent Citations (1)
Title |
---|
T. UCHIDA ET AL.: "Optimization of Preparative Cnditions for Polylactide (PLA) Microspheres Containing Ovalbumin", CHEMICAL AND PHARMACEUTICAL BULLETIN, vol. 43, no. 9, 1 September 1995 (1995-09-01), Tokyo (jp), pages 1569 - 1573, XP000533273 * |
Also Published As
Publication number | Publication date |
---|---|
JP2010174021A (ja) | 2010-08-12 |
CN1602186A (zh) | 2005-03-30 |
BRPI0213226B1 (pt) | 2016-03-01 |
ES2541908T3 (es) | 2015-07-28 |
EP1450766A1 (fr) | 2004-09-01 |
EP1450766B1 (fr) | 2015-04-22 |
AU2002358831B2 (en) | 2007-09-06 |
MXPA04003433A (es) | 2004-08-11 |
CA2463358A1 (fr) | 2003-04-17 |
US7691412B2 (en) | 2010-04-06 |
JP2005509611A (ja) | 2005-04-14 |
BR0213226A (pt) | 2004-12-21 |
CA2463358C (fr) | 2012-03-13 |
CN100518828C (zh) | 2009-07-29 |
US20060110460A1 (en) | 2006-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1450766B1 (fr) | Microspheres biodegradables a liberation prolongee et leur procede de preparation | |
EP0585151B1 (fr) | Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues | |
JP2010174021A6 (ja) | 徐放型生物分解性微小球およびその製造方法 | |
BE1004486A3 (fr) | Formulations a liberation prolongee de peptides solubles dans l'eau. | |
JP6494657B2 (ja) | 徐放特性を持つペプチド充填plgaミクロスフェアの調製 | |
US20170281548A1 (en) | Organic Compounds | |
FR2810885A1 (fr) | Microparticule a liberation soutenue et procede de fabrication | |
WO1993001802A1 (fr) | Composition pour la liberation prolongee et controlee d'une substance medicamenteuse peptidique et procede pour sa preparation | |
FR2691631A1 (fr) | Compositions contenant des sels de peptides formés avec des polyesters à terminaison carboxy et procédés pour leur production. | |
WO1993007861A1 (fr) | Preparation et utilisations de microspheres a plusieurs phases | |
JP2013177406A (ja) | オクトレオチドおよび2種またはそれ以上のポリラクチドコグリコリドポリマーを含む徐放性製剤 | |
JP5713897B2 (ja) | 生理活性ペプチドを含有する微粒子を調製するためのプロセス | |
EP0804173B1 (fr) | Microspheres biodegradables a liberation controlee et leur procede de preparation | |
JP2012501321A (ja) | 溶媒交流蒸発法による徐放性マイクロスフェアの製造方法 | |
CN1438881A (zh) | 胰岛素控释制剂及其方法 | |
FR2748205A1 (fr) | Compositions pharmaceutiques pour la liberation controlee de principes actifs insolubles | |
FR2830448A1 (fr) | Microspheres biodegradables a liberation prolongee et leur procede de preparation | |
JP7030720B2 (ja) | 先端巨大症、先端巨大症がん、sst-r5発現腫瘍、2型糖尿病、高血糖症、及びホルモン関連腫瘍の治療において使用するための、生理学的条件において難溶性であるベルドレオチド | |
CN117427046A (zh) | 一种用于装载多肽类药物的缓释微球及其制备方法 | |
WO2003043605A1 (fr) | Procede de preparation de microparticules sans solvant toxique, microparticules obtenues selon ce procede, utilisations et compositions pharmaceutiques |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR CA CN JP MX US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FR GB GR IE IT LU MC NL PT SE SK TR US |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2463358 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003533903 Country of ref document: JP Ref document number: PA/A/2004/003433 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002358831 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004/03065 Country of ref document: ZA Ref document number: 200403065 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002793162 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002824575X Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2002793162 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006110460 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10492417 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10492417 Country of ref document: US |